Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse

Panelists discuss how recent advancements in the treatment of newly diagnosed multiple myeloma (MM) and early relapse, particularly the role of chimeric antigen receptor T-cell therapy, are reshaping therapeutic strategies and improving patient outcomes.

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

October 18th 2024

Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

October 18th 2024

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

October 25th 2024

Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

October 25th 2024

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

November 1st 2024

Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

November 1st 2024

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.